RNA Technologies Expand Tool Kit for Cancer Immunotherapy
Elie Dolgin • October 1, 2019
Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.
Continue reading at Cancer Discovery.
This ancient oddball fills a major gap in the fossil record.
Jaw-dropping patient videos and miraculous testimonials ignited a frenzy in China over a technique that aims to improve drainage from the brain. Now it is entering trials worldwide.